Physician profile
Keren Holmes
NPI 1871614370
$57,633.69
in general payments reported to CMS, 2019-2025
38 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,442 · 2020: $203 · 2021: $1,462 · 2022: $998 · 2023: $647 · 2024: $23K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Consulting Fee: $8,800 · Food and Beverage: $6,439 · Travel and Lodging: $2,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,800.00 |
| Consulting Fee | $8,800.00 |
| Food and Beverage | $6,438.57 |
| Travel and Lodging | $2,489.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $50,361.71 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $1,295.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $992.68 | 2019-2025 | |
| Abbvie INC. | $873.38 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $625.80 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $453.49 | 2019-2025 | Repatha, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $303.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.32 | 2019-2025 | Jardiance, Jascayd, Ofev |
| Abbott Laboratories | $228.82 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $225.42 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $200.66 | 2019-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Exact Sciences Corporation | $191.89 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $183.51 | 2019-2024 | |
| Glaxosmithkline, LLC. | $160.88 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $125.96 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keren Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.